Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

IntroductionSPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety an...

Full description

Bibliographic Details
Main Authors: Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
castration resistant prostate cancer
PSMA
radioligand therapy
PNT2002
dosimetry
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1483953/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1483953/full

Similar Items